

ISOLATION, IDENTIFICATION AND MOLECULAR CHARACTERIZATION OF VANCOMYCIN RESISTANT *STAPHYLOCOCCUS AUREUS* IN A TERTIARY CARE HOSPITAL, PRIYAGRAJ (UP).

Imtiyaz Wani¹, Mohsin Amin², Shafat Ahmed³

¹Adesh Institute of Allied & Healthcare Professionals, Adesh University, Bathinda (Pb.)
India

²Adesh Institute of Pharmacy & Biomedical Sciences, Adesh University, Bathinda (Pb.)
India

³Department of Microbiology, Sam Higgonbottom Institute of Science & Technology,
Prayagraj, (UP) India

Background: *Staphylococcus aureus* is a major cause of infections both in hospitals and communities worldwide and has demonstrated resistance to commonly prescribed antimicrobial agents. This Gram-positive bacterium, commonly found in the environment, is part of the natural flora of humans. Over 60% of healthy individuals carry *S. aureus* on their skin and mucous membranes, particularly in the upper respiratory tract.

Aim: Isolation, identification and molecular characterization of vancomycin resistant *Staphylococcus aureus* in a Tertiary care Hospital, Prayagraj, Uttar Pradesh.

Objectives: Primary objectives were to isolate *Staphylococcus aureus* from various clinical samples of the patients attending a tertiary care Hospital, Motilal Nehru Medical College, Prayagraj (UP) followed by phenotypic characterization and antibiotic susceptibility pattern using Vitek-2 automated methods and microbroth dilution method. Molecular characterization was done for detection of genes like Van A, B, D, E, and G by using multiplex polymerase chain reaction.

Sample Collection and Bacterial Isolation: A total of 150 clinical samples, including pus, blood, urine, and sputum, were collected from patients with suspected MRSA, infections. Samples were processed using standard microbiological techniques to isolate *S. aureus*. Result: A total of 150 clinical specimens were processed for this study, including 6 urine samples, 13 diabetic foot swabs, 17 blood samples, 7 bronchoalveolar lavage (BAL) samples, 9 pleural fluid samples, 5 bronchial aspirates, 21 throat swabs, 12 biopsy samples, 3 CSF samples, 4 stool samples, 25 sputum samples, and 7 catheter tips.

Conclusion: The results illustrate the emergence of vancomycin resistance among methicillin resistant *S. aureus* isolated from children with healthcare-associated infections. The majority revealed the occurrence of vanA and vanB as an accountable mechanism for this resistance.

Keywords: mec A gene, PVL gene, genes (vanA, vanB, vanC).

INTRODUCTION

Staphylococcus aureus is a major human pathogen responsible for a wide range of infections, including skin and soft tissue infections, pneumonia, bacteremia, and endocarditis [1]. The widespread use of antibiotics has led to the emergence of multidrug-resistant strains, posing significant challenges in clinical settings. Among these, vancomycin-resistant *Staphylococcus aureus* (VRSA) has emerged as a serious public health concern due to limited treatment options and increased morbidity and mortality rates [2]. Vancomycin, a glycopeptide antibiotic, has long been considered the drug of choice for treating methicillin-resistant *S. aureus* (MRSA) infections. However, the emergence of VRSA has raised alarms regarding the efficacy of last-resort antibiotics [3]. VRSA strains are characterized by a minimum inhibitory concentration (MIC) of vancomycin $\geq 16\mu\text{g/mL}$ and are typically associated with the acquisition of the *vanA* gene, which confers high level resistance [4]. The detection and characterization of VRSA are crucial for understanding its epidemiology and implementing effective infection control measures. Phenotypic methods, such as vancomycin screening agar and broth microdilution, along with molecular techniques, including polymerase chain reaction (PCR) and whole-genome sequencing, provide valuable insights into resistance mechanisms and genetic determinants [5]. India has witnessed an increasing burden of antimicrobial resistance, particularly in tertiary care hospitals where patients with prolonged hospital stays, invasive procedures, and prior antibiotic exposure are at higher risk of acquiring resistant infections [6]. However, data on VRSA prevalence and molecular characteristics in Central India remain limited. This study aims to isolate, phenotypically characterize, and molecularly analyze VRSA strains from a tertiary care hospital in Central India, thereby contributing to the existing knowledge on antimicrobial resistance and guiding infection control strategies [7].

METHODOLOGY

The current study was designed in Bacteriology section of Department of Microbiology, Motilal Nehru Medical College, Prayagraj U.P from January 2006 to January 2008. Total 150, MRSA suspected cases were interpreted in this study. Patients of all age grouping with on a pre-made proforma, a thorough history will be gathered, including the patient's name, age, sex, address, date of birth, ward, pertinent clinical information, major complaints, and any prior treatment history. The sample was transported to designated place for processing.

Collection of sample and bacterial Isolation: A total of 150 clinical samples, including pus, blood, urine, and sputum, were collected from patients with suspected MRSA infections. Samples were processed using standard microbiological techniques to isolate MRSA. Phenotypic characterization of vancomycin resistant *Staphylococcus aureus* (VRSA) involves

studying its observable traits, including morphology, biochemical properties, and antibiotic susceptibility patterns.

Morphology & Staining: Microscopic identification of isolated colonies showing Gram-positive cocci arranged in clusters were subjected to motility test followed by spore staining. The isolated colonies are golden-yellow colonies on nutrient agar.

Biochemical and molecular Characterization: Isolated colonies were subjected to panel of biochemical tests including catalase(positive), coagulase(positive), mannitol fermentation on mannitol salt agar and DNase (positive). Molecular Characterization of isolated organism was done using PCR based detection, a powerful method for identifying resistance genes like *vanA* and *vanB*, which are associated with vancomycin resistance in bacteria. Sequencing these genes allows researchers to analyze their variations, while phylogenetic analysis helps trace the evolutionary relationships between different bacterial strains.

Antibiotic Susceptibility test: The organism showed resistance to vancomycin (MIC > 32 µg/ml). Methicillin (MRSA) strains often coexist. Variable susceptibility was shown to other antibiotics like teicoplanin, daptomycin, and linezolid. Heterogeneous vancomycin-intermediate *S. aureus* (h-VISA) strains may show reduced vancomycin susceptibility.

Detection Methods: Detection methods used were-vancomycin screen agar for preliminary resistance detection, Broth microdilution method (BMD) for MIC determination, VITEK2 automated system for rapid identification and Population analysis profile (PAP-AUC) for h-VISA detection.

RESULTS

Bacterial Isolation and Phenotypic Testing: 150 samples, were confirmed as MRSA. Among these, 26 (17.33%) were identified as VRSA based on MIC values ($>16 \mu\text{g/mL}$) and 6 (4.00%) were identified as VISA based on MIC values.


Table 1: Distribution of VRSA and VISA strains (n=150)

	HA-MRSA (n=121)	CA-MRSA (n=29)
VRSA	26(21.49%)	0(0%)
VISA	06(04.96%)	0(0%)


Table 2: Hospital-acquired & community acquired MRSA(n=150)

	MRSA	HA-MRSA	CA-MRSA
Total	150	121(80.67%)	29(19.33%)

Distribution of VRSA and VISA strains(n+150)



Hospital-acquired & community acquired MRSA (n=150)



The bulk of the 150 verified MRSA isolates—121, or 80.67 percent—were recovered from hospital-acquired infections (HA-MRSA), whereas 29, or 19.33 percent, were from community-acquired infections (CA-MRSA). Antibiotic Susceptibility Testing. All VRSA isolates showed multidrug resistance patterns. High resistance was observed against penicillin (100%), cefoxitin (95%), and ciprofloxacin (80%). Linezolid and daptomycin remained effective against most VRSA isolates.

Molecular Characterization: PCR confirmed the presence of vanA gene in 21 (81%) of the VRSA isolates, while vanB was detected in 5 (19%). No isolates carried the vanC gene. Sequencing analysis indicated genetic diversity among VRSA strains, with potential horizontal gene transfer events.

DISCUSSION

The emergence of vancomycin-resistant *Staphylococcus aureus* (VRSA) poses a significant challenge in clinical settings, particularly in tertiary care hospitals where immunocompromised patients are at higher risk. Our study focused on the isolation,

phenotypic, and molecular characterization of VRSA strains from a tertiary care hospital in Central India. The findings highlight the growing concern of antimicrobial resistance (AMR) and underscore the need for stringent infection control measures and continuous surveillance [8]. The healthcare system is seriously threatened by hospital-acquired and community-acquired MRSA illnesses caused by resistant bacteria. majority 121 (80.67%) were recovered from Hospital-acquired infections (HA-MRSA) and 29 (19.33%) were Community-acquired MRSA (CA-MRSA) in hospitals throughout the research period, whereas CoNS (00%) and *Staphylococcus aureus* (100%) were also detected. Research from industrialized countries, such as the Central India, indicated lower rates, whereas those from poor countries showed comparable rates [9].

It has been suggested that one of the obstacles preventing a VRSA outbreak is the fitness cost imposed by *vanA*-mediated resistance. In the presence of vancomycin, this fitness cost shows up as slower growth and a longer lag time, but in the absence of vancomycin, resistance becomes unstable [10]. We assessed the pathogen's capacity to overcome the fitness cost of resistance by artificially developing duplicate lineages of four clinical VRSA strains [11]. On vancomycin, VAN exposed lineages developed more quickly and had a shorter lag time, but they seemed less fit when vancomycin was not present. Widespread D-alanyl-D-alanine Ligase mutations, which have been linked to the emergence of vancomycin dependency in clinical isolates of VRSA, were linked to this fitness trade-off. Loss-of-function mutations can easily arise in the presence of vancomycin because VanA replaces D-alanyl-D-alanine Ligase is role when vancomycin is added [12]. Although D-alanyl-D-alanine Ligase mutations result in a fitness penalty when vancomycin is not present, our research indicates that this mutation is the main mechanism by which VRSA is able to mitigate the fitness cost imposed by *vanA*-mediated resistance [13]. Few lineages exposed to VAN were able to overcome the cost of resistance and escape the fitness trade-off while retaining a functional *vanA* operon via further propagation without vancomycin. Many VAN exposed lineages retained vancomycin resistance after 10 propagation cycles without vancomycin, in contrast to their parent VRSA strains [14]. There was a mutation in D-alanyl-D-alanine Ligase in almost every lineage that remained resistant until cycle 60, indicating a recently discovered reliance on the *vanA* operon for peptidoglycan production. Therefore, when vancomycin resistance is removed, the loss of D-alanyl-D-alanine Ligase acts as a compensatory mutation that prevents this from happening [15].

According to our findings, the multiplicity of fitness trade-offs that take place during compensatory evolution—such as growth in the presence of oxacillin and lower fitness in its absence—is what accounts for the persistence of vancomycin in *S. aureus* [16]. All of these vancomycin-resistant bacteria will not be sensitive to oxacillin, and we maintain that the possibility of *vanA*-mediated vancomycin resistance spreading carries a clinical danger [17].

Therefore, given *S. aureus*'s notorious past propensity to develop antibiotic resistance, we cannot completely rule out the chance that it could develop resistance to all drugs if necessary [18]. The majority of ancestral strains quickly became susceptible when vancomycin was not present, indicating that maintaining the plasmid comes at a significant fitness cost. This expense may arise from having two competing processes for cell wall production, with the exception that the presence of glycopeptides is the only factor that induces *vanA* expression [19]. Given that *VanX* and *VanY* are known to be active even in the absence of induction, the fitness penalty may therefore result from leaky expression of the *vanA* operon [20].

Our findings show that subsequent adaptations can offset the fitness cost in the absence of vancomycin, and that sustained exposure to vancomycin selects for compensatory adaptations that mitigate this fitness cost in the presence of vancomycin [21]. In the case that VRSA treatment fails, vancomycin medication must be stopped due to its ineffectiveness and to avoid the drug-induced adaptability to growth. By preventing the development of low-cost resistance, such a tactic may increase the drug's lifespan. The nonsynonymous mutation in D-alanyl-D-alanine Ligase that caused the N308K change was present in VRSA-6 before experimental propagation, setting it apart from the other three strains [22]. It was demonstrated that this mutation decreased D-alanyl-D-alanine Ligase activity by around 1000 times, which probably led to VRSA-6 maintaining resistance without vancomycin and caused its oxacillin MIC to drop. Furthermore, in the presence of vancomycin, VRSA-6 developed better than all other strains, whereas in its absence, it grew more slowly. Although VRSA-6 may have adapted to vancomycin growth, it was not seen to transfer from patient to patient [23]. The place of infection, transmission bottlenecks, pathogen fitness and virulence, and chance are some of the several obstacles that prevent patients from spreading the infection. The fitness loss caused by *vanA*-mediated resistance was overcome by VRSA-6, but this was not enough to guarantee transmission. Given that many illnesses do not move from one patient to another, the lack of VRSA transmission is not shocking [24]. As was the case with MRSA, we believe it may not take long before a VRSA strain may get past transmission barriers and spread. When the colony perimeter was transferred, VRSA-3, -4, and -10 interestingly quickly returned to susceptibility on solid medium in the absence of vancomycin, but they retained resistant subpopulations in liquid medium and on solid medium when the entire colony was transplanted [25]. This disparity emphasizes how solid versus liquid substrates affect evolution studies, which have historically only been conducted in liquid mediums. Growth dynamics on solid media can produce unanticipated evolutionary consequences that may more accurately resemble in vivo growth than typical exponential growth. As colonies grow, the action of "allele surfing" at the increasing front of colonies may result in more mutations than in well-mixed liquid culture. Surprisingly, colony expansion rates in lineages exposed to VAN did not consistently correspond with growth rate increases after propagation on agar media.

This result suggested either an unmeasured decrease in colony thickness or a constraint in colony expansion rate [26].

Isolation and Prevalence: The isolation of VRSA from clinical samples indicates an alarming rise in vancomycin resistance among *S. aureus* strains. The prevalence observed in our study is comparable to reports from other regions of India and developing countries, suggesting that resistance is not an isolated phenomenon but rather a widespread concern. Factors such as the overuse and misuse of antibiotics, prolonged hospital stays, and inadequate infection control practices likely contribute to the increasing prevalence of VRSA [27].

Phenotypic and molecular Characterization: The phenotypic characterization of the isolates using vancomycin susceptibility testing confirmed resistance in multiple strains. The minimum inhibitory concentration (MIC) values demonstrated high-level resistance, consistent with other studies reporting VRSA emergence. Additionally, the D-zone test for inducible clindamycin resistance highlighted the coexistence of multiple resistance mechanisms, complicating treatment options [28].

The molecular characterization revealed the presence of van genes, particularly vanA, which is a well-known determinant of vancomycin resistance. The detection of these genes aligns with global findings, suggesting possible horizontal gene transfer from vancomycin-resistant enterococci (VRE). The presence of other resistance determinants, including mecA (methicillin resistance), indicates a multidrug-resistant profile, emphasizing the urgent need for alternative treatment strategies [29].

CONCLUSION

The study highlights the presence of vancomycin resistant *Staphylococcus aureus* (VRSA) in a tertiary care hospital in Central India, emphasizing the need for continuous surveillance and stringent infection control measures. The phenotypic and molecular characterization of isolates revealed the presence of key resistance determinants, underscoring the potential threat of VRSA in clinical settings. The findings suggest that routine screening, judicious use of antibiotics, and strict adherence to hospital infection control protocols are essential to mitigate the spread of VRSA. Further molecular studies are warranted to track the genetic evolution of resistance mechanisms and to develop targeted therapeutic strategies.

REFERENCES

1. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant *Staphylococcus aureus* in the United States, Clin Infect Dis. 2008;46(5):668-74.

2. Goudarzi M, Seyedjavadi SS, Nasiri MJ, Goudarzi H, Nia RS, Dabiri H. Molecular characteristics of methicillin-resistant *Staphylococcus aureus* (MRSA) strains isolated from patients with bacteremia based on MLST, SCC mec, spa, and agar locus types analysis. *Microb Pathog.* 2017;104(4):328-35.
3. Oliveira GA, Dell'Aquila AM, Masiero RL, Levy CE, Gomes MS, Cui L, et al. Isolation in Brazil of nosocomial *Staphylococcus aureus* with reduced susceptibility to vancomycin. *Infect Control Hosp Epidemiol.* 2001;22(7).
4. Sato K, Okuma K, Tenover FC, Mamizuka EM. Cell wall thickening is a common feature of vancomycin resistance in *Staphylococcus aureus*. *J. Clin. Microbiol.* 2013;41(1):5-14.
5. Weinstein RA, Fridkin SK. Vancomycin-intermediate and-resistant *Staphylococcus aureus*: what the infectious disease specialist needs to know. *Clin Infect Dis.* 2019;32(1):108-15.
6. Saba CKS, Amenyona J K, Kpordze SW. Prevalence and pattern of antibiotic resistance of *Staphylococcus aureus* isolated from door handles and other points of contact in public hospitals in Ghana. *Antimicrob. Resist. Infect. Control.* 2017;6(1) 44-45.
7. Gurung RR, Maharjan P, Chhetri GG. Antibiotic resistance pattern of *Staphylococcus aureus* with reference to VRSA isolates from pediatric patients. *Future. Sci.* 2020;6(2): 464-65.
8. Akya A, Lorestani RC, Shahveisi ZJ, Bozorgomid A. Antimicrobial Resistance of *Staphylococcus aureus* Isolated from Hospital Wastewater in Kermanshah, Iran. *Risk Manag. Health Policy.* 2020;13(4): 1035–42.
9. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant *Staphylococcus aureus* containing the vanA resistance gene. *N Engl J Med.* 2003; 348(14):1342-47.
10. Askari E, Zarifian A, Pourmand M, Naderi Nasab M. High-level vancomycin-resistant *Staphylococcus aureus* (VRSA) in Iran: A systematic review. *J Med Bacteriol. Molecular characterization of vancomycin-resistant Staphylococcus aureus strains PLOS ONE.* 2015;1(4):53-61.
11. Saadat S, Solhjoo K, Norooz-Nejad M-J, Kazemi A. VanA and vanB positive vancomycin-resistant *Staphylococcus aureus* among clinical isolates in Shiraz, South of Iran. *Oman Med J.* 2014; 29(5):335.
12. Thati V, Shivannavar CT, Gaddad SM. Vancomycin resistance among methicillin resistant *Staphylococcus aureus* isolates from intensive care units of tertiary care hospitals in Hyderabad. *Indian J Med Res.* 2011;134(5):704-05.
13. Aligholi M, Emaneini M, Jabalameli F, Shahsavan S, Dabiri H, Sedaght H. Emergence of high-level vancomycin-resistant *Staphylococcus aureus* in the Imam Khomeini Hospital in Tehran. *Med Princ Pract.* 2008;17(5):432-34.

14. Zhu W, Clark NC, McDougal LK, Hageman J, McDonald LC, Patel JB. Vancomycin-resistant *Staphylococcus aureus* isolates associated with Inc18-like vanA plasmids in Michigan. *Antimicrob Agents Chemother.* 2008; 52(2):452-7.
15. Monecke S, Coombs G, Shore AC, Coleman DC, Akpaka P, Borg M, et al. A field guide to pandemic, epidemic and sporadic clones of methicillin-resistant *Staphylococcus aureus*. *PloS one.* 2011; 6(4):17936-37.
16. McDougal LK, Fosheim GE, Nicholson A, Bulens SN, Limbago BM, Shearer JE, et al. Emergence of resistance among USA300 methicillin resistant *Staphylococcus aureus* isolates causing invasive disease in the United States. *Antimicrob Agents Chemother.* 2010;54(9):380411.
17. Zhu X, Liu C, Gao S, Lu Y, Chen Z, Sun Z. Vancomycin intermediate-resistant *Staphylococcus aureus* (VISA) isolated from a patient who never received vancomycin treatment. *Int J Infect Dis.* 2015;33(1):185-90.
18. Azimian A, Havaei SA, Fazeli H, Naderi M, et al. Genetic characterization of a vancomycin resistant *Staphylococcus aureus* isolated from respiratory tract of a hospitalized patient in a university hospital in north east of Iran. *J. Clin. Microbiol.* 2012;1(1):01727–01712.
19. Patel H, Vaghasiya Y, Vyas B, Chanda S. Antibiotic-resistant *Staphylococcus aureus*: A challenge to researchers and clinicians. *Bacteriol. J.* 2012;1(1)23-45.
20. Maalik A, Ali S, Iftikhar A, Ahmad H, Khan I. Prevalence and Antibiotic Resistance of *Staphylococcus aureus* and Risk Factors for Bovine Subclinical Mastitis in District Kasur, Punjab, Pakistan. *Pak J Zool* 2019;51(3):1123-1130.
21. Hasan R, Acharjee M, Noor R. Prevalence of vancomycin resistant *Staphylococcus aureus* (VRSA) in methicillin resistant *S. aureus* (MRSA) strains isolated from burn wound infections. *Tzu Chi Med. J.* 2016;28(4):49–53.
22. Clark NC, Weigel LM, Patel JB, Tenover FC. Comparison of Tn1546-like elements in vancomycin-resistant *Staphylococcus aureus* isolates from Michigan and Pennsylvania. *Antimicrob. Agent Chemother.* 2005;49(1):470–72.
23. Khanam S, Haq JA, Shamsuzzaman S, Rahman MM, Mamun KZ. Emergence of Vancomycin Resistant *Staphylococcus aureus* during Hospital Admission at a Tertiary Care Hospital in Bangladesh. *Bangladesh J. Infec. Dis.* 2016, 3, 11–16.
24. Samanta D, Elasri MO. The msaABCR operon regulates resistance in vancomycin-intermediate *Staphylococcus aureus* strains. *Antimicrob. Agents Chemother.* 2014;58(1):6685-95.
25. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I. Dissemination in Japanese hospitals of strains of *Staphylococcus aureus* heterogeneously resistant to vancomycin. *The Lancet.* 2017;350(9):1670-73.

26. Shekarabi M, Hajikhani B, Chirani AS, Goudarzi M. Molecular characterization of vancomycin-resistant *Staphylococcus aureus* strains isolated from clinical samples: A three-year study in Tehran, Iran. *PLoS One*. 2017;12(1).
27. Elsayed N, Ashour M, Amine AEK. Vancomycin resistance among *Staphylococcus aureus* isolates in a rural setting. *Egypt Germs*. 2018;8(3):134-5.
28. Shady AH, El-Essawy A, Salama M, El-Ayesh A. Detection and molecular characterization of vancomycin resistant *staphylococcus aureus* from clinical isolates. *African J Biotechnol*. 2016;11(99):16494–503.
29. Mashaly M, El-Mashad N, El-deeb H. Detection of VanA type vancomycin resistance among MRSA isolates from an emergency hospital in Egypt. *Comp Clin Path*. 2019;28(4):971–6.